2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Apoptosis
  3. Reactive Oxygen Species (ROS) Apoptosis Bcl-2 Family Caspase SHMT Methylenetetrahydrofolate Dehydrogenase (MTHFD) Cytochrome P450
  4. Anticancer agent 310

Anticancer agent 310 is an antitumor agent. Anticancer agent 310 releases nitric oxide to induce mitochondrial ROS burst, triggers mitochondrial dysfunction and activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 apoptotic pathway. Anticancer agent 310 also reduces the levels of SHMT2 and MTHFD2, decreases the ratios of NADPH/NADP+ and GSH/GSSG, thereby disrupting redox homeostasis and exacerbating intracellular ROS accumulation. Anticancer agent 310 can be used in research related to gastric cancer.

For research use only. We do not sell to patients.

Anticancer agent 310

Anticancer agent 310 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 310 Related Antibodies

Top Publications Citing Use of Products

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All SHMT Isoform Specific Products:

View All Isoforms
SHMT1 SHMT2

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms
CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 310 is an antitumor agent. Anticancer agent 310 releases nitric oxide to induce mitochondrial ROS burst, triggers mitochondrial dysfunction and activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 apoptotic pathway. Anticancer agent 310 also reduces the levels of SHMT2 and MTHFD2, decreases the ratios of NADPH/NADP+ and GSH/GSSG, thereby disrupting redox homeostasis and exacerbating intracellular ROS accumulation. Anticancer agent 310 can be used in research related to gastric cancer[1].

In Vitro

Anticancer agent 310 (compound A9) (0.016-10 μM; 72 h) potently inhibits the proliferation of various human and murine tumor cell lines in vitro[1].
Anticancer agent 310 (1.6-40 nM; 12-14 days) inhibits the long-term colony-forming ability of HGC27 and AGS gastric cancer cells in a concentration-dependent manner[1].
Anticancer agent 310 (50-100 μM; 2 h) releases nitric oxide in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (2 μM; 12 h) induces mitochondrial ROS burst in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (2 μM) induces mitochondrial membrane potential depolarization in HGC27 and AGS gastric cancer cells, and this effect is reversed by ROS scavenging[1].
Anticancer agent 310 (2 μM; 36 h) induces apoptosis in HGC27 and AGS gastric cancer cells[1].
Anticancer agent 310 (0.5-2 μM; 24 h) activates the Bax/Bcl-2-Cyt c-Caspase-9/Caspase-3 mitochondrial apoptotic pathway in HGC27 and AGS gastric cancer cells in a dose-dependent manner in vitro[1].
Anticancer agent 310 (0.5-2 μM; 24 h) downregulates SHMT2 and MTHFD2, key enzymes in the folate one-carbon metabolic pathway, in HGC27 and AGS gastric cancer cells in a dose-dependent manner by inhibiting the transcription factor ATF4[1].
Anticancer agent 310 (2 μM; 12 h) disrupts redox homeostasis in HGC27 and AGS gastric cancer cells and reduces the ratios of NADPH/NADP+ and GSH/GSSG[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 310 Related Antibodies

Cell Viability Assay[1]

Cell Line: MCF-7, HepG2, HCT-116, HGC27, U251, AGS, ES-2, A2780, K562, MEG01, CT26
Concentration: 0.016, 0.08, 0.4, 2, 5, 10 μM
Incubation Time: 72 h
Result: Exhibited sub-micromolar inhibitory activity across all tested cell lines, with IC50 values as follows: MCF-7: 0.19 μM; HepG2: 0.21 μM; HCT-116: 0.22 μM; HGC27: 0.10 μM; U251: 0.14 μM; AGS: 0.02 μM; ES-2: 0.12 μM; A2780: 0.11 μM; K562: 0.12 μM; MEG01: 0.40 μM; CT26: 0.26 μM.

Apoptosis Analysis[1]

Cell Line: HGC27, AGS
Concentration: 2 μM
Incubation Time: 36 h
Result: Increased total apoptotic cells in HGC27 cells from 10.99% (control) to 83.1%.
Induced a total apoptotic rate of 60.9% in AGS cells.

Western Blot Analysis[1]

Cell Line: HGC27, AGS
Concentration: 0.5, 1, 2 μM
Incubation Time: 24 h
Result: Upregulated the expression of cytoplasmic cytochrome c, Bax, Cleaved Caspase-9, and Cleaved Caspase-3, and downregulated the expression of mitochondrial cytochrome c and Bcl-2 in a dose-dependent manner in both HGC27 and AGS cells.
In Vivo

Anticancer agent 310 (5-15 mg/kg; intratumoral injection; once daily; for 14 consecutive days) exhibits dose-dependent in vivo anti-gastric cancer activity in NCG mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NCG mice treated HGC27 tumor fragments[1]
Dosage: 5 mg/kg; 10 mg/kg; 15 mg/kg
Administration: intratumoral; daily; 14 days
Result: Reduced tumor weight relative to control at 5 mg/kg dose.
Achieved 95.3% tumor growth inhibition (TGI), with 4 out of 6 mice showing complete tumor regression at 10 mg/kg dose.
Achieved 98.78% TGI, with 5 out of 6 mice showing complete tumor regression at 15 mg/kg dose.
Decreased expression of Ki67, SHMT2, and MTHFD2 in tumor tissues relative to control group at 10 mg/kg and 15 mg/kg doses.
Caused no obvious body weight loss or mortality in any dose group.
Molecular Weight

684.71

Formula

C33H36N2O12S
SMILES

O=C1OCC2=C1CC[C@@]3(C)[C@@]2([H])C[C@H]4[C@]5(O4)[C@@]36[C@@H](O6)[C@H](O7)[C@@]7(C(O)(C)C)[C@H]5OC(CCCCOC8=NON=C8S(=O)(C9=CC=CC=C9)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 310 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 310Anticancer agent310Anticancer agent-310Reactive Oxygen Species (ROS)ApoptosisBcl-2 FamilyCaspaseSHMTMethylenetetrahydrofolate Dehydrogenase (MTHFD)Cytochrome P450Serine hydroxymethyltransferaseCYPsGSH/GSSGxenograft mouse modelsSHMT2Bax/Bcl-2Cyt cCaspase-9Caspase-3apoptotic pathwayMTHFD2folate one-carbon metabolismAGS cellsgastric cancer cellsredox homeostasisNADPH/NADP+Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 310
Cat. No.:
HY-182284
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.